FDA Urges Lower Target for ESA Use; Market Could Drop By More Than Half.
CMS Launches National Coverage Analysis, Citing FDA’s Black Box Warning on ESAs.
FDA Purges Quality of Life Claims from Oncology Label for ESAs.
Amgen Says It Can Demonstrate Safety of Existing Hg Target.
If You Were On ODAC: Experts Suggest Questions For May 10 Advisory Meeting.
Trending Stories
- Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology - She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- Imaging’s ride to the bottom in clinical trials—and why it matters now
- HHS seems poised to exert control over USPSTF
Ransohoff: The task force is the pinnacle of evidence-based medicine - The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic - First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI